Abstract
A metabolically stable and centrally acting analog of pGlu-Glu-Pro-NH2 ([Glu2]TRH, a tripeptide structurally related to TRH (thyrotropin-releasing hormone)) was designed by replacing the amino-terminal pyroglutamyl residue with a pyridinium moiety. The analeptic action of the analog was used to optimize the efficacy of this novel CNS agent when administered intravenously in its CNS-permeable prodrug forms obtained via the reduction of the pyridinium moiety to the nonionic dihydropyridine and esterifying the central Glu with various alcohols. The maximum effect in antagonizing pentobarbital-induced narcosis in mice was achieved with the hexyl ester that was used subsequently for a comparative evaluation with a prodrug of the parent neuropeptide in the Porsolt swim test as a paradigm for antidepressant effect. The novel analog maintained its antidepressant potency but showed reduced analeptic action compared to [Glu2]TRH; thus, an increase in the selectivity of CNS-action was obtained by the incorporation of the pyridinium moiety.
Keywords: [glu2]trh, central nervous system permeable prodrugs, analeptic effect, antidepressant, porsolt swim test, immobilized artificial membrane chromatography
Medicinal Chemistry
Title: A Pyridinium-substituted Analog of the TRH-like Tripeptide pGlu-Glu- Pro-NH2 and its Prodrugs as Central Nervous System Agents
Volume: 1 Issue: 2
Author(s): K. Prokai-Tatrai, M. Teixido, V. Nguyen, A. D. Zharikova and L. Prokai
Affiliation:
Keywords: [glu2]trh, central nervous system permeable prodrugs, analeptic effect, antidepressant, porsolt swim test, immobilized artificial membrane chromatography
Abstract: A metabolically stable and centrally acting analog of pGlu-Glu-Pro-NH2 ([Glu2]TRH, a tripeptide structurally related to TRH (thyrotropin-releasing hormone)) was designed by replacing the amino-terminal pyroglutamyl residue with a pyridinium moiety. The analeptic action of the analog was used to optimize the efficacy of this novel CNS agent when administered intravenously in its CNS-permeable prodrug forms obtained via the reduction of the pyridinium moiety to the nonionic dihydropyridine and esterifying the central Glu with various alcohols. The maximum effect in antagonizing pentobarbital-induced narcosis in mice was achieved with the hexyl ester that was used subsequently for a comparative evaluation with a prodrug of the parent neuropeptide in the Porsolt swim test as a paradigm for antidepressant effect. The novel analog maintained its antidepressant potency but showed reduced analeptic action compared to [Glu2]TRH; thus, an increase in the selectivity of CNS-action was obtained by the incorporation of the pyridinium moiety.
Export Options
About this article
Cite this article as:
Prokai-Tatrai K., Teixido M., Nguyen V., Zharikova D. A. and Prokai L., A Pyridinium-substituted Analog of the TRH-like Tripeptide pGlu-Glu- Pro-NH2 and its Prodrugs as Central Nervous System Agents, Medicinal Chemistry 2005; 1 (2) . https://dx.doi.org/10.2174/1573406053175256
DOI https://dx.doi.org/10.2174/1573406053175256 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Technology Development Studio of the MPI-CBG: An Open Access Cell-Based Screening Facility
Combinatorial Chemistry & High Throughput Screening Recent Progress in the Development of Adenosine Receptor Ligands as Antiinflammatory Drugs
Current Topics in Medicinal Chemistry Obstructive Sleep Apnoea Syndrome and Diabetes. Fortuitous Association or Interaction?
Current Diabetes Reviews Depression as a Comorbidity in Behcet's Syndrome
CNS & Neurological Disorders - Drug Targets Progress in Developing D3 Dopamine Receptor Ligands as Potential Therapeutic Agents for Neurological and Neuropsychiatric Disorders
Current Pharmaceutical Design Impacts of Pseudo Amino Acid Components and 5-steps Rule to Proteomics and Proteome Analysis
Current Topics in Medicinal Chemistry Brain Tumor Causes, Symptoms, Diagnosis and Radiotherapy Treatment
Current Medical Imaging Possible Neuroprotective Strategies for Huntingtons Disease
Current Neuropharmacology Mental Health of Children of Immigrants and Ethnic Minorities in Europe
Adolescent Psychiatry Constitutively Activated G Protein-Coupled Receptors: A Novel Approach to CNS Drug Discovery
Current Drug Targets - CNS & Neurological Disorders Structure-Activity Relationships for Serotonin Transporter and Dopamine Receptor Selectivity
Medicinal Chemistry Sialuria-Related Intellectual Disability in Children and Adolescent of Pakistan: Tenth Patient Described has a Novel Mutation in the GNE Gene
CNS & Neurological Disorders - Drug Targets Monoaminergic Neurotransmission: The History of the Discovery of Antidepressants from 1950s Until Today
Current Pharmaceutical Design Recent Patents on Immunoregulatory DNA Vaccines for Autoimmune Diseases and Allograft Rejection
Recent Patents on DNA & Gene Sequences Polyphenols: Well Beyond The Antioxidant Capacity: Polyphenol Supplementation and Exercise-Induced Oxidative Stress and Inflammation
Current Pharmaceutical Biotechnology Microwave Assisted Prospective Synthesis of New 5-Arylidene Rhodanine Derivatives Bearing a 3-[4-(3-Aminopropyl)piperazin-1-yl]propyl Side Chain
Current Microwave Chemistry Experimental and Computational Studies on the Inhibition of Acetylcholinesterase by Curcumin and Some of its Derivatives
Current Computer-Aided Drug Design Oral Fast-Release Solid Dispersion-Paradigm Shift to Nanoparticles
Recent Patents on Drug Delivery & Formulation Current Status and Future Prospective of Immunointervention in Multiple Sclerosis
Current Medicinal Chemistry Synthetic Glucocorticoids: Antenatal Administration and Long-term Implications
Current Pharmaceutical Design